Can you be a surrogate with herpes? In most cases, yes. Herpes simplex virus (HSV) — both oral (HSV-1) and genital (HSV-2) — is one of the most common viral infections in the world.
Roughly one in six adults in the U.S. has genital herpes. Many of them have had healthy pregnancies. Many are surrogates.
What matters isn’t whether you have herpes — it’s whether the infection is managed. Well-managed HSV, on suppressive antiviral therapy and without active lesions at delivery, is not a disqualifier at Physician’s Surrogacy. It requires physician review and a managed delivery protocol. It doesn’t require you to stop pursuing surrogacy.
Key Takeaways
•Herpes (HSV-1 or HSV-2) does not automatically disqualify you from becoming a gestational surrogate.
•Well-managed HSV on suppressive antiviral therapy is typically compatible with surrogacy — with appropriate clinical protocols.
•The primary clinical concern is preventing neonatal herpes transmission — which suppressive therapy and a managed delivery protocol address directly.
•Active genital lesions near delivery require a C-section — a delivery management decision, not an eligibility barrier.
•At Physician’s Surrogacy, our OB/GYN team evaluates your HSV history clinically — not through a blanket exclusion policy.
How Herpes Is Evaluated in Surrogacy Screening
Quick Answer
HSV doesn’t affect the embryo, the uterus, or the transfer process. The clinical concern in surrogacy is neonatal herpes — transmission to the baby during a vaginal delivery if active genital lesions are present. Suppressive antiviral therapy throughout the third trimester dramatically reduces this risk, and a C-section delivery eliminates it entirely when lesions are present at term.
The medical framework for managing herpes in pregnancy is well-established. Acyclovir and valacyclovir have been used safely in pregnant women for decades.
Starting suppressive therapy at 36 weeks is standard obstetric practice for women with a known HSV history.
The surrogacy context adds one layer: full disclosure to the intended parents, and documentation in the surrogacy agreement. That’s not unique to herpes — it’s standard for any relevant medical history.
HSV-1 vs. HSV-2 — Does the Strain Matter?
HSV-1 (typically oral herpes)
HSV-1 most commonly causes oral cold sores, not genital lesions. Genital HSV-1 does occur but is typically associated with fewer outbreaks and lower transmission risk than HSV-2. A history of oral HSV-1 — which affects an estimated 67% of adults — is generally not a clinical concern for surrogacy. Genital HSV-1 is evaluated the same way as HSV-2.
HSV-2 (genital herpes)
HSV-2 is the strain most commonly associated with genital outbreaks and the one most relevant to surrogacy screening. It’s manageable. Suppressive antiviral therapy, started at 36 weeks, reduces outbreak frequency and viral shedding. Delivery management — C-section if active lesions are present — addresses the neonatal transmission risk directly. This is a clinical protocol, not a barrier to candidacy.
Primary (first-time) HSV infection during pregnancy
A primary HSV infection acquired for the first time during pregnancy carries a significantly higher risk of neonatal transmission than recurrent outbreaks — because the mother hasn’t yet developed full antibody protection. This scenario is evaluated very differently from an established, well-managed herpes history. Primary infections acquired during a surrogate pregnancy would require urgent clinical management.
What Research Shows: Suppressive Therapy and Neonatal Herpes Risk
A randomized controlled trial published in the New England Journal of Medicine found that suppressive acyclovir therapy beginning at 36 weeks reduced HSV recurrences at delivery by 75% and significantly reduced the need for C-section delivery in women with recurrent genital herpes. Neonatal herpes transmission rates in women with recurrent HSV on suppressive therapy are extremely low — estimated at less than 1 in 1,000 deliveries.
In plain terms: suppressive therapy works. The combination of third-trimester antivirals and delivery management reduces neonatal herpes risk to a clinically acceptable level. This is established medicine, not experimental.
The Physician’s Advantage
HSV Is a Managed Condition — Physicians Understand That
Most agencies flag herpes and stop. Our OB/GYN team knows that well-managed HSV on suppressive therapy is compatible with a safe surrogate pregnancy. They write the protocol — not the screening form.
Physician’s Surrogacy is the only U.S. surrogacy agency managed by practicing OB/GYNs — with a preterm delivery rate 50% below the national average.
Our physician-designed screening protocol goes beyond ASRM guidelines.
If You’re Currently on Suppressive Therapy:
Knowing your current antiviral medication, dosage, and outbreak frequency in the last 12 months is helpful information for the physician evaluation. You don’t need this before applying — the initial application is a basic eligibility check. But having it ready speeds up the screening phase.
Surrogate Compensation at Physician’s Surrogacy
A herpes history does not affect your compensation if you are medically cleared. Pay is set by your state and experience.
First-time surrogates earn a flat-rate package starting at $60,000–$75,000+ by state. Included: household allowance, childcare support, maternity clothing, lost wages. No receipts, no reimbursement filing. Medical care, legal fees, and travel are covered separately by the intended parents.
A $1,250 pre-screening completion bonus applies once you complete the initial screening phase. See our full surrogate compensation breakdown for details.
Apply in 10 Minutes
Herpes Is One of the Most Manageable Conditions in Obstetric Care
Don’t let a stigmatized condition stop you from applying. The initial application takes 10 minutes. Our physician team reviews the clinical details — not the diagnosis label.
First-time surrogates start at $60,000–$75,000+ — with an average match time of one week.
Become a Surrogate →
Frequently Asked Questions
Can herpes be passed to the intended parents’ baby? +
Neonatal herpes — transmission of HSV to the baby during delivery — is the primary clinical concern. It occurs most commonly when a mother has active genital lesions at the time of vaginal delivery, particularly during a primary (first-time) infection. Suppressive antiviral therapy starting at 36 weeks significantly reduces the risk. A C-section delivery eliminates the exposure route if active lesions are present at term.
Do I have to tell the intended parents I have herpes? +
Yes. Full medical disclosure is required in gestational surrogacy. Herpes history — including current management — is shared with intended parents during the matching process and documented in the surrogacy agreement. This is standard and non-negotiable across all reputable agencies.
Is it safe to take antiviral medication while pregnant? +
Yes. Acyclovir and valacyclovir have extensive safety data in pregnancy. They’ve been used by pregnant women for decades and are classified as generally safe for use during pregnancy by major obstetric guidelines. Starting suppressive therapy at 36 weeks is a standard recommendation for pregnant women with a history of genital herpes.
What if I have very infrequent outbreaks — does that affect my eligibility? +
Infrequent outbreaks are a positive indicator. Viral shedding and transmission risk are generally lower in women with infrequent or well-suppressed HSV. Our physician team considers outbreak frequency as part of the evaluation — it’s relevant context, not irrelevant history.
Does herpes affect surrogate compensation? +
No. If you are medically cleared to proceed, compensation is determined by your state and experience level — not your medical history.
The information in this article is for educational purposes only and does not constitute medical advice. Always consult your prescribing physician and your medical team regarding medication management and pregnancy safety.
Julianna Nikolic
Chief Strategy Officer Julianna Nikolic leads strategic initiatives, focusing on growth, innovation, and patient-centered solutions in the reproductive sciences sector. With 26+ years of management experience and a strong entrepreneurial background, she brings deep expertise to advancing reproductive healthcare.
